• Member Statistics

    • 731,300 Colleagues-to-Date [Sponsored by a generous R&D grant from iMBA, Inc.]
  • Our ME-P Channels

  • ME-P Archives Silo [2006 – 2018]

  • Dr. David Marcinko [Publisher-in-Chief]

    As a Distinguished University Professor and Endowed Department Chairman, Dr. David Edward Marcinko MBBS DPM MBA MEd BSc CMP® was a NYSE broker and investment banker for a decade who was respected for his unique perspectives, balanced contrarian thinking and measured judgment to influence key decision makers in strategic education, health economics, finance, investing and public policy management.

    Dr. Marcinko is originally from Loyola University MD, Temple University in Philadelphia and the Milton S. Hershey Medical Center in PA; Oglethorpe University and Atlanta Hospital & Medical Center in GA; and Aachen City University Hospital, Koln-Germany. He is one of the most innovative global thought leaders in health care entrepreneurship today by leveraging and adding value with strategies to grow revenues and EBITDA while reducing nonessential expenditures and improving operational efficiencies.

    Professor Marcinko was a board certified physician, surgical fellow, hospital medical staff Vice President, public and population health advocate, and Chief Executive & Education Officer with more than 425 published papers; 5,150 op-ed pieces and over 135+ domestic / international presentations to his credit; including the top ten [10] biggest drug and pharmaceutical companies and financial services firms in the nation. He is also a best-selling Amazon author with 30 published text books in four languages [National Institute of Health, Library of Congress and Library of Medicine].

    Dr. Marcinko is past Editor-in-Chief of the prestigious “Journal of Health Care Finance”, and a former Certified Financial Planner® who was named “Health Economist of the Year” in 2010, by PM magazine. He is a Federal and State court approved expert witness featured in hundreds of peer reviewed medical, business, economics and trade publications [AMA, ADA, APMA, AAOS, Physicians Practice, Investment Advisor, Physician’s Money Digest and MD News] etc.

    Dr. Marcinko is also an early-stage investor with a focus on finance, economics and business IT. He was on the initial team for Physicians-Nexus®, 1st. Global Financial Advisors and Physician Services Group Inc; and as a mentor for Deloitte-Touche, Accenture and other start-ups in Silicon Valley, CA.

    As a licensed life and health insurance agent, RIA – SEC registered representative, Dr. Marcinko was Founding Dean of the fiduciary niche focused CERTIFIED MEDICAL PLANNER® online chartered designation education program; as well as Chief Editor of the HEALTH DICTIONARY SERIES® Wiki Project.

    Dr. Marcinko’s professional memberships included: ASHE, AHIMA, ACHE, ACME, ACPE, MGMA, FMMA and HIMSS. He was a MSFT Beta tester, Google Scholar, “H” Index favorite and one of LinkedIn’s “Top Cited Voices”. Marcinko is “ex-officio” and R&D Scholar-on-Sabbatical for iMBA, Inc. who was recently appointed to the MedBlob® [military encrypted medical data warehouse and health information exchange] Advisory Board.

    entrepreneur

    Frontal_lobe_animation

  • Hope Hetico RN MS [Managing Editor]

    Prof. Hetico

     

     

     

     

    ME-P SYNDICATIONS:
    WSJ.com,
    CNN.com,
    Forbes.com,
    WashingtonPost.com,
    BusinessWeek.com,
    USNews.com, Reuters.com,
    TimeWarnerCable.com,
    e-How.com,
    News Alloy.com,
    and Congress.org

    Comprehensive Financial Planning Strategies for Doctors and Advisors: Best Practices from Leading Consultants and Certified Medical Planners(TM)

    Product Details

    Product Details

    Product Details

  • CERTIFIED MEDICAL PLANNER® program

    New "Self-Directed" Study Option SinceJanuary 1st, 2018
  • PodiatryPrep.org


    BOARD CERTIFICATION EXAM STUDY GUIDES
    Lower Extremity Trauma
    [Click on Image to Enlarge]

  • Most Recent ME-Ps

  • ME-P Free Adverting Sales Consultation

    The “Medical Executive-Post” is about connecting doctors, health care executives and modern consulting advisors. It’s about free-enterprise, business, practice, policy, personal financial planning and wealth building capitalism. We have an attitude that’s independent, outspoken, intelligent and so Next-Gen; often edgy, usually controversial. And, our consultants “got fly”, just like U. Read it! Write it! Post it! “Medical Executive-Post”. Call or email us for your FREE advertising and sales consultation TODAY [770.448.0769]

    Product Details

    Product Details

  • Medical & Surgical e-Consent Forms

    ePodiatryConsentForms.com
  • iMBA White Papers

    Customized Industry Topics [$1,500 unlimited corporate license]January 1st, 2018
    Medical Clinic Valuations * Endowment Fund Management * Health Capital Formation * Investment Policy Statement Analysis * Provider Contracting & Negotiations * Marketplace Competition * Revenue Cycle Enhancements; and more! HEALTHCARE FINANCIAL INDUSTRIAL COMPLEX
  • Ann Miller RN MHA [Executive-Director]

    iMBA VIRTUAL OFFICES [1.770.448.0769] Atlanta, GA.
    Location doesn't matter. We welcome new long-distance clients and colleagues.

  • ME-P Publishing

  • SEEKING INDUSTRY PARTNERS?

    If you want the opportunity to work with leading health care industry insiders, innovators and watchers, the “ME-P” may be right for you? We are unbiased and operate at the nexus of theoretical and applied R&D. Collaborate with us and you’ll put your brand in front of a smart & tightly focused demographic; one at the forefront of our emerging healthcare free marketplace of informed and professional “movers and shakers.” Our Ad Rate Card is available upon request [770-448-0769].

  • Reader Comments, Quips, Opinions, News & Updates

  • Start-Up Advice for Businesses, DRs and Entrepreneurs

    ImageProxy “Providing Management, Financial and Business Solutions for Modernity”
  • Up-Trending ME-Ps

  • Capitalism and Free Enterprise Advocacy

    Whether you’re a mature CXO, physician or start-up entrepreneur in need of management, financial, HR or business planning information on free markets and competition, the "Medical Executive-Post” is the online place to meet for Capitalism 2.0 collaboration. Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds. ******************************************************************** THE ME-P DISCLAIMER: Posts, comments and all opinions do not necessarily represent iMBA, Inc. Copyright © 2006 to-date.
  • OIG Fraud Warnings

    Beware of health insurance marketplace scams OIG's Most Wanted Fugitives at oig.hhs.gov
  • Advertisements

Should Drugs be Discontinued If DNA Predicts Risks?

On Pharmacogenetic Testing and Genomics – An Invitation

[By Karen D. Matthias RN MBA]

Dr. Marcinko and ME-P Readers

Wouldn’t it be wonderful to test someone’s DNA and know the right drug to prescribe at the right dose the first time without the worry of adverse side effects?  Pharmacogenetics—the manner in which a person’s genes affect their response to drugs, has the potential to do just that.  Genetic and genomic tests hold enormous promise for revolutionizing our medical understanding of a disease.

However, it is irresponsible to suggest that a simple genetic test, at this point in time, can appropriately dictate prescribing practices for certain drugs.

Pharmacogenetic Testing

The use of pharmacogenetic testing in the diagnosis and treatment of cancer has recently created a lot of questions for patients.  A high profile example is whether or not genetic tests can predict the risk of recurrence of breast cancer in women taking tamoxifen.

Our knowledge of how genetics and environment interact to dictate an individual’s response to a given drug is in its infancy. Therefore it is critically important that there is sufficient evidence to support the use of a given test before it is introduced into mainstream medical practice. In most cases, there is not a simple single genetic test that will give us the necessary information.

For example, Hayes has reviewed the evidence behind the pharmacogenetics of response to tamoxifen, and the reality is that there is currently insufficient evidence to conclude that performing a genetic test prior to prescribing this drug has any impact at all on patient outcomes.

Link: http://www.hayesinc.com/hayes/?s=Tamoxifen+

Assessment 

Furthermore, well-designed studies are needed to both confirm the relationship between genetic variants and response to tamoxifen. The critical component is to show that positive changes in patient care can be made in response to the results of genetic testing and to establish what the potential negative repercussions of NOT prescribing these drugs to patients may be.  It is possible that the benefits outweigh the risks, even for patients shown by genetic testing to be less likely to respond to treatment.

Join Our Mailing List 

ME-P Invitation from Hayes, Inc 

Dr. Diane J. Allingham-Hawkins would be available to give you, and your ME-P readers, a perspective on this ongoing genetics testing dialogue. Dr. Allingham-Hawkins is Director of the Genetics Test Evaluation Program at Hayes, Inc., an unbiased, healthcare research and consulting firm that is helping hospitals and insurers cope with the cost and ethical issues related to genetic testing.  She is an outspoken interviewee with deep knowledge of the subject matter and very pointed opinions regarding genetic testing.  A great interview for your consideration.

Contact Info:

Karen D. Matthias – Vice President

Hayes, Inc – 157 S. Broad Street

Lansdale, PA 19446

P: 215-855-0615 x7918

E-mail: kmatthias@hayesinc.com

Channel Surfing the ME-P

Have you visited our other topic channels? Established to facilitate idea exchange and link our community together, the value of these topics is dependent upon your input. Please take a minute to visit. And, to prevent that annoying spam, we ask that you register. It is fast, free and secure.

Conclusion

Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com

OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:

Product DetailsProduct Details

 

Advertisements

2 Responses

  1. DNA and the Genome

    The United States has proposed analyzing genetic information from more than 1 million American volunteers as part of a new initiative to understand human disease and develop medicines targeted to an individual’s genetic make-up.

    http://www.msn.com/en-us/news/us/us-proposes-effort-to-analyze-dna-from-1-million-people/ar-AA8LI37?ocid=iehp

    Dr. David Edward Marcinko MBA

    Like

  2. 7.2% of People Age 17-25 Reported Illicit Drug Addiction or Misuse in 2015

    JAMA recently released an infographic on mental health and substance use disorders. Here are some key findings on drug abuse:

    • 2.9% of Americans over age 12 reported illicit drug addiction or misuse in 2015.
    • For females over age 12, 2% reported illicit drug addiction or misuse in 2015.
    • 3.8% of males over age 12 reported illicit drug addiction or misuse in 2015.
    • For people age 12-17, 3.4% reported illicit drug addiction or misuse in 2015.
    • 7.2% of people age 17-25 reported illicit drug addiction or misuse in 2015.
    • For people over age 26, 2.1% reported illicit drug addiction or misuse in 2015.


    Source:
    JAMA, August 1, 2017

    Like

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s

%d bloggers like this: